Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Puretech Health PLC    PRTC   GB00BY2Z0H74

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Sector news Biotechnology & Medical Research - NEC
07/26 Autos and energy firms boost European shares as earnings roll in, banks held ..
07/25DJCELGENE : Settles Lawsuit Over Improper Promotion of Cancer Drugs
07/25DJELI LILLY AND : to Delay Arthritis Drug Application -- Market Talk
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
07/12 FDA panel backs Novartis' pioneering new cancer gene therapy
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
06/15DJACTELION : J&J Maps Research Plans for Actelion -- WSJ
06/14DJACTELION : Correction to J&J Actelion Story
06/14DJACTELION : J&J Plans to Add Drug Discovery and Early Research to Actelion Unit
06/14 JOHNSON & JOHNSON : flu drug succeeds in mid-stage trial
06/09 ACTELION : Johnson & Johnson expects to complete Actelion purchase on June 16
06/09 ACTELION : Johnson & Johnson expects to complete of Actelion offer on June 16
06/02DJBluebird Bio stock jumps 7% after Maxim Group upgrades to buy -- MarketWatch
05/31 GILEAD SCIENCES : and GSK go head-to-head with similar HIV drug data
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
05/07 REGENERON SHARES POISED FOR REBOUND : Barron's
05/07 REGENERON PHARMACEUTICALS : shares poised for rebound - Barron's
05/02 JACK MA : Temasek, Yunfeng lead $75 million funding into China genomics firm
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27 AMGEN : Cost controls help offset lower Amgen first-quarter drug sales
04/26 New GlaxoSmithKline CEO wants fewer, bigger new drug launches
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
04/18DJACTELION : J&J Lifts Forecast on Actelion Tie-Up--Update
04/18DJJOHNSON & JOHNSON : Lifts Forecast on Actelion Tie-Up
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug -- Up..
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug
03/31 ACTELION : J&J declares Actelion tender offer a success, sees closing in second ..
03/31DJJOHNSON & JOHNSON : Says Tender Offer to Buy Actelion Successful
03/30 China's Creat makes 1.2 billion euro bid for German blood plasma firm
03/28DJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
03/28DJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
03/14 AstraZeneca ovarian cancer drug slows disease markedly in study
03/09 Bull market turns 8 - historical facts and figures
03/09 Germany's Merck well advanced in talks to sell biosimilars unit
03/08 Compare and contrast - Trump's tweets vs private comments to CEOs
03/07 Drugmaker shares slip as Trump tweets about pricing system
03/06DJINCYTE : Race Tightens for Next Wave of Cancer Drugs
03/02DJACTELION : Founders Start New Biotech, With J&J's Backing
Financials ($)
Sales 2017 1,85 M
EBIT 2017 -100 M
Net income 2017 -66,8 M
Debt 2017 4,43 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 223x
EV / Sales 2018 207x
Capitalization 408 M
Sector Biotechnology & Medical Research - NEC